Cart
sales@molnova.com
OT-551 HCl
CAS No. 627085-15-8
OT-551 HCl( —— )
Catalog No. M34368 CAS No. 627085-15-8
OT-551 HCl is an NF-Κb inhibitor, a disubstituted hydroxylamine with antioxidant properties can be used for the treatment of cataracts and age-related macular degeneration and geographic atrophy (GA).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 295 | In Stock |
|
| 5MG | 245 | In Stock |
|
| 10MG | 363 | In Stock |
|
| 25MG | 562 | In Stock |
|
| 50MG | 786 | In Stock |
|
| 100MG | 1088 | In Stock |
|
| 200MG | 1460 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameOT-551 HCl
-
NoteResearch use only, not for human use.
-
Brief DescriptionOT-551 HCl is an NF-Κb inhibitor, a disubstituted hydroxylamine with antioxidant properties can be used for the treatment of cataracts and age-related macular degeneration and geographic atrophy (GA).
-
DescriptionOT-551 HCl is an NF-Κb inhibitor, a disubstituted hydroxylamine with antioxidant properties can be used for the treatment of cataracts and age-related macular degeneration and geographic atrophy (GA).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetNF-κB
-
RecptorNF-κB
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number627085-15-8
-
Formula Weight277.79
-
Molecular FormulaC13H24ClNO3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCl.CC1(C)CC(CC(C)(C)N1O)OC(=O)C1CC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
14-Deoxy-1112-didehy...
14-Deoxy-1112-didehydroandrographolide has hypotensive anti-inflammatory anti-asthma and anti-cancer actions. It can inhibit NF-κB activation.
-
Cynaropicrin
Cynaropicrin, a sesquiterpene lactone found in artichoke (Cynara scolymus), has anti-hepatitis C and trypanosome activity and inhibits NF-κB activation.
-
CL075
CL075 (3M002) is a selective TLR8 agonist with immunomodulatory activity, triggering the MyD88-dependent signaling pathway and activating NF-κB and IRF7 to elicit the production of inflammatory cytokines and type I interferon (IFN).
